Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 73.33B |
| Revenue (ttm) | 13.85B |
| Net Income (ttm) | 4.65B |
| Shares Out | 107.59M |
| EPS (ttm) | 40.43 |
| PE Ratio | 16.86 |
| Forward PE | 14.84 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,106,836 |
| Open | 705.34 |
| Previous Close | 693.23 |
| Day's Range | 681.13 - 707.48 |
| 52-Week Range | 666.25 - 1,211.20 |
| Beta | 0.09 |
| Analysts | Buy |
| Price Target | 1,024.28 (+50.28%) |
| Earnings Date | Feb 4, 2025 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2023, Regeneron Pharmaceuticals's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.
Financial StatementsAnalyst Forecast
According to 25 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $1,024.28, which is an increase of 50.28% from the latest price.
News
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals...
Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals...
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options If you ...
Regeneron Pharmaceuticals Inc. Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for...
Regeneron: Phase III Success In Skin Cancer For Libtayo
Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition, contribu...
Long-term possibilities in healthcare are unbelievable, says Jim Cramer
'Mad Money' host Jim Cramer looks at several healthcare stocks and shares his perspective on their trajectory in 2025.
Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc....
Jim Cramer says he supports healthcare stocks for their long-term value
CNBC's Jim Cramer on Tuesday opined on the importance of investing for the long term, telling investors it's wise to evaluate certain pharmaceutical stocks for their growth prospects. "Ask yourself wh...
Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who pu...
Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Should Contact the Shareholders Foundation in Connection With Lawsuit
The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron Pharmace...
Regeneron Pharmaceuticals, Inc. (REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 January 13, 2025 5:15 PM ET Company Participants Leonard Schleifer - Board Co-Chair, Co-Founder, Presi...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Regeneron Pharmaceuticals Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Urged To Contact The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for...
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Dupixent ® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD ® and EYLE...
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo
Truveta sells stakes to Regeneron, Illumina in deal to build genetic database
Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake in the company as part of a deal to build the w...
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
The Truveta collaboration will extend Regeneron Genetics Center's ® (RGC TM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 10, 2025 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
NEW YORK , Jan. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). Shareholders who purchased shares of REGN dur...
Regeneron Pharmaceuticals Inc Is Being Sued For Securities Law Violations And Impacted Investors Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc...
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
LOS ANGELES, CA / ACCESSWIRE / January 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc...
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2024 financial and operating resu...
Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025
Regeneron Pharmaceuticals continues to show strong growth, driven by Dupixent's FDA approval for COPD and Eylea HD's market resilience against biosimilars. Q3 earnings beat expectations with $3.72 bil...
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations an...
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January ...
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI Worl...